Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Cancer Cell. 2021 Mar 8;39(3):310-345. doi: 10.1016/j.ccell.2020.11.009. Epub 2020 Dec 17.
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.
与传统的化疗药物不同，靶向抗癌药物旨在抑制支持肿瘤发生或肿瘤进展的精确分子改变。尽管具有如此高的分子特异性，但许多临床应用和实验性靶向抗癌药物也介导免疫刺激或免疫抑制作用，这些作用（至少在某些情况下）会影响治疗效果。在这里，我们讨论了靶向抗癌药物的主要免疫调节作用，并探讨了利用这些作用以支持更高临床疗效的潜在途径。
